Changes in the32P incorporation in rat mammary tumor after chronic administration of LH-RH analogs

Georges Cehovic, Tommie W. Redding, Andrew V Schally

Research output: Contribution to journalArticle

Abstract

We studied endogenous phosphorylation in rat transplantable MT/W9A hormone-dependent mammary tumors of untreated rats and of animals treated with LH-RH analogs, the agonist d-Trp-6-LH-RH and the antagonist N-Ac-d-p-Cl-Phe1,2, d-Trp3, d-Arg6, d-Ala10-LH-RH. Incorporation of32P from32P-ATP was reduced significantly in tumors of rats treated with agonistic and antagonistic analogs of LH-RH or ovariectomized. The inhibition of protein phosphorylation may be related to tumor regression.

Original languageEnglish
Pages (from-to)243-247
Number of pages5
JournalMedical Oncology and Tumor Pharmacotherapy
Volume2
Issue number4
DOIs
StatePublished - Dec 1 1985
Externally publishedYes

Fingerprint

Gonadotropin-Releasing Hormone
Breast Neoplasms
Phosphorylation
Neoplasms
Adenosine Triphosphate
Hormones
Proteins

Keywords

  • P incorporation
  • LH-RH treatment
  • MT-W9A mammary tumor

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Oncology
  • Medicine(all)

Cite this

Changes in the32P incorporation in rat mammary tumor after chronic administration of LH-RH analogs. / Cehovic, Georges; Redding, Tommie W.; Schally, Andrew V.

In: Medical Oncology and Tumor Pharmacotherapy, Vol. 2, No. 4, 01.12.1985, p. 243-247.

Research output: Contribution to journalArticle

@article{84694d00f7fe43f78bc28369566e4cf9,
title = "Changes in the32P incorporation in rat mammary tumor after chronic administration of LH-RH analogs",
abstract = "We studied endogenous phosphorylation in rat transplantable MT/W9A hormone-dependent mammary tumors of untreated rats and of animals treated with LH-RH analogs, the agonist d-Trp-6-LH-RH and the antagonist N-Ac-d-p-Cl-Phe1,2, d-Trp3, d-Arg6, d-Ala10-LH-RH. Incorporation of32P from32P-ATP was reduced significantly in tumors of rats treated with agonistic and antagonistic analogs of LH-RH or ovariectomized. The inhibition of protein phosphorylation may be related to tumor regression.",
keywords = "P incorporation, LH-RH treatment, MT-W9A mammary tumor",
author = "Georges Cehovic and Redding, {Tommie W.} and Schally, {Andrew V}",
year = "1985",
month = "12",
day = "1",
doi = "10.1007/BF02934909",
language = "English",
volume = "2",
pages = "243--247",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "4",

}

TY - JOUR

T1 - Changes in the32P incorporation in rat mammary tumor after chronic administration of LH-RH analogs

AU - Cehovic, Georges

AU - Redding, Tommie W.

AU - Schally, Andrew V

PY - 1985/12/1

Y1 - 1985/12/1

N2 - We studied endogenous phosphorylation in rat transplantable MT/W9A hormone-dependent mammary tumors of untreated rats and of animals treated with LH-RH analogs, the agonist d-Trp-6-LH-RH and the antagonist N-Ac-d-p-Cl-Phe1,2, d-Trp3, d-Arg6, d-Ala10-LH-RH. Incorporation of32P from32P-ATP was reduced significantly in tumors of rats treated with agonistic and antagonistic analogs of LH-RH or ovariectomized. The inhibition of protein phosphorylation may be related to tumor regression.

AB - We studied endogenous phosphorylation in rat transplantable MT/W9A hormone-dependent mammary tumors of untreated rats and of animals treated with LH-RH analogs, the agonist d-Trp-6-LH-RH and the antagonist N-Ac-d-p-Cl-Phe1,2, d-Trp3, d-Arg6, d-Ala10-LH-RH. Incorporation of32P from32P-ATP was reduced significantly in tumors of rats treated with agonistic and antagonistic analogs of LH-RH or ovariectomized. The inhibition of protein phosphorylation may be related to tumor regression.

KW - P incorporation

KW - LH-RH treatment

KW - MT-W9A mammary tumor

UR - http://www.scopus.com/inward/record.url?scp=0022270074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022270074&partnerID=8YFLogxK

U2 - 10.1007/BF02934909

DO - 10.1007/BF02934909

M3 - Article

C2 - 2935686

AN - SCOPUS:0022270074

VL - 2

SP - 243

EP - 247

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 4

ER -